

Image

1642

PATENT

Case Docket No. MAXIM.026C3

Date: February 19, 2004


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hellstrand et al.  
Appl. No. : 10/076,306  
Filed : February 12, 2002  
For : ENHANCED ACTIVATION OF  
NATURAL KILLER CELLS  
USING AN NK CELL  
ACTIVATOR AND A  
HYDROGEN PEROXIDE  
SCAVENGER OR INHIBITOR  
Examiner : Holleran, A.L.  
Group Art Unit : 1642

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 19, 2004

(Date)

  
Mallery K. de Merlier, Reg. No. 51,609


TRANSMITTAL LETTER


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with four (4) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Mallery K. de Merlier  
Registration No. 51,609  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



## INFORMATION DISCLOSURE STATEMENT

Applicant : Hellstrand et al.  
App. No. : 10/076,306  
Filed : February 12, 2002  
For : ENHANCED ACTIVATION OF  
NATURAL KILLER CELLS USING AN  
NK CELL ACTIVATOR AND A  
HYDROGEN PEROXIDE SCAVENGER  
OR INHIBITOR  
Examiner : Holleran, Anne L.  
Group Art Unit : 1642

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 4 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,


KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/19/04

By: Mallory K. de Merlier

Mallory K. de Merlier  
Registration No. 51,609  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.026C3	APPLICATION NO. 10/076,306
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand et al.	
		FILING DATE February 12, 2002	GROUP 1642



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Bacon et al. (1995) Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. Journal of Experimental Medicine. 181:399-404.
	2	Nelson et al. (1998) Biology of the interleukin-2 receptor. Advances in Immunology. 70:1-81.
	3	Presky et al. (1996) A functional interleukin 12 receptor complex is composed of two $\beta$ -type cytokine receptor subunits. Proc. Natl. Acad. Sci. 93:14002-14007.
	4	Wolf et al. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Journal of Immunology. 146(9):3074-3081.

S:\DOCS\MKD\MKD-4082.DOC\021904

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	